Anti-CD123 CAR NK cells therapy(Chongqing Precision Biotechnology)

N/A

Report date: 2024/12/13 20:00:39

Base Information

Drug NameAnti-CD123 CAR NK cells therapy(Chongqing Precision Biotechnology)
Drug Alias NameCD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) cells therapy(Chongqing Precision Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD123Natural killer cell replacements
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsNeoplasms, Plasma CellLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms, Plasma CellLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A